Research programme: antibody therapeutics - Astellas/MorphoSys
Latest Information Update: 25 Jul 2024
At a glance
- Originator Astellas Pharma
- Class Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Undefined in Japan
- 05 Apr 2007 Preclinical trials in Undefined in Japan (unspecified route)